AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02106871 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sildenafil
Description: 50mg of Sildenafil daily for 4 weeks
Study NCT02046993 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced usual care
Description: Encouraged to do HBP measurement and record BP readings in paper diary
Study NCT02046993 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced usual care
Description: Encouraged to do HBP measurement and record BP readings in paper diary
Study NCT02062541 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Funct. assessment+fast rehabilitation
Study NCT00404287 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluvastatin
Study NCT02000726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT02000726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram
Study NCT02000726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fast acting antidepressant-like treatment. administered i.v. during the fMRI scanning session
Description: Fast acting antidepressant-like treatment administered intravenously for 35 min. during the fMRI scanning session.
Study NCT02062541 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Funct. assessment+usual rehabilitation
Study NCT02062541 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: usual assessment+fast rehabilitation
Study NCT01343238 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: 12 week diet behavior modification
Study NCT01343238 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 12 week exercise behavioral intervention
Study NCT01343238 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet and Exercise
Description: 12 week diet and exercise behavioral modification intervention
Study NCT03890133 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ba-Duan-Jin
Description: Ba-Duan-Jin is a common form of self-healthcare Qigong exercise that has been practiced by Chinese people for at least eight hundred years.It consists of eight sets of simple movements. By combining meditation with slow, graceful movements,deep breathing, and relaxation, Ba-Duan-Jin practitioners believe it has the ability to move vital energy (Qi) throughout the body. Ba-Duan-Jin is also considered to be a multicomponent intervention that integrates physical, psychosocial, emotional, spiritual, and behavioral elements. While the biological mechanisms remain unclear.
Study NCT02106871 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: 50mg of Sildenafil daily for 4 weeks
Study NCT03507673 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood samples and microbiological swaps
Description: Blood analysis and analysis of vaginal microbiota.
Study NCT01653522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptan
Study NCT01131910 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TBE-vaccine
Description: Solution of 0.5 ml for intramuscular use. Given in 2 doses separated by 1 month to healthy individuals less than 60 years old. (3 doses 0+1+3 months to those are 60 and above in Sweden)
Study NCT01131910 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TBE-vaccine
Description: Solution for injection 0.5 ml im. 2 or 3 doses first years, 1 dose next year
Study NCT01131910 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccination against TBE
Description: 0.5 ml im at 0 and 1 month ( less than 60 years old) or 0 and 1 and 3 months (at least 60 years old)
Study NCT01965730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epsilon-aminocaproic acid (EACA)
Study NCT01965730 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epsilon-aminocaproic acid (EACA)
Study NCT03005132 — intervention group
Intervention type: OTHER
Intervention: Normal brain tissue
Description: The investigators will extract total protein, DNA and RNA from the samples.
Study NCT00746863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.125% Marcaine
Description: Patients randomized to the intervention arm will receive 60 cc of 0.125% Marcaine injected into the retropubic space along the tract that the suprapubic mid-urethral trocar will follow (one on each side) for a total of 120 cc of 0.125% Marcaine, prior to the placement of the mid-urethral sling via the suprapubic approach.
Study NCT03094117 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: News items with spin
Description: Interpretation of news items with spin
Study NCT03094117 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: News items without spin
Description: Interpretation of news items without spin
Study NCT02475278 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NoV GI.1/GII.4 Bivalent VLP Vaccine
Description: Norovirus GI.1/GII.4 bivalent VLP vaccine adjuvanted with aluminum hydroxide for IM injection
Study NCT01653522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Study NCT00640510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapid Acting Intramuscular Olanzapine
Description: 10mg/injection, IM. If patients do not respond to the first study medication or if patients do not have enough improvement based on the investigator's judgment, and in addition, if the investigator judges it is reasonable, the patient will receive a second injection at the same dose strength as the first injection after 2 hours following the first injection (no later than 8 hours after the first injection).
Study NCT00640510 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic sodium chloride solution
Description: 0.9% sodium chloride (NaCl) solution. If patients do not respond to the first study medication or if patients do not have enough improvement based on the investigator's judgment, and in addition, if the investigator judges it is reasonable, the patient will receive a second injection at the same dose strength as the first injection after 2 hours following the first injection (no later than 8 hours after the first injection).
Study NCT02163291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel liposome
Description: S-1 40 mg/m2 bid d1-14 po and paclitaxel liposome 175mg/m2 d1 intravenously infusion for 3 hours, every 3 weeks. After 2 cycles' treatment, if clinical response is complete response（CR）,partial regression（PR） or stable disease（SD）, another 2 cycles is administered and operation is performed after the total 4 cycles. If response is progressive disease（PD）, chemotherapy is stopped and operation is performed.
Study NCT02243150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G1T28-1 (CDK 4/6 Inhibitor)
Study NCT03890133 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin capsule
Description: Pregabalin is one of the three medications (pregabalin, duloxetine, and milnacipran) that have been approved by the Food and Drug Administration (FDA) to treat fibromyalgia in US, and the only medicine that has been approved in China.
Study NCT02818582 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GS-5734
Description: Daily GS-5734 delivered intravenously (IV) for 5 days
Study NCT02818582 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Placebo delivered intravenously (IV) for 5 days.
Study NCT02223624 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: walking and light weights
Study NCT02223624 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: walking and light weights
Study NCT02223624 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eccentric aerobic exercise
Study NCT02223624 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: concentric aerobic exercise
Study NCT00401310 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: Placebo IV infusions 1hr/daily over 7 days.
Study NCT00401310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: MK0724
Description: MK0724 8 mg/kg/hr 1 hr/daily over 7 days.
Study NCT03948321 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Aminolevulinic acid photodynamic therapy
Description: Aminolevulinic acid photodynamic therapy
Study NCT03948321 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Aminolevulinic acid photodynamic therapy
Description: Aminolevulinic acid photodynamic therapy
Study NCT02353234 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bread
Description: In each arm subjects consume bread
Study NCT03088566 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The D-Foot method
Description: The D-Foot method is a standardised routine of foot screening. The D-Foot i web program aimed to be used on a surf plate.
Study NCT03088566 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional foot screening
Description: The foot screening is performed with clinical conventional methods.
Study NCT00253071 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prophylactic combined medical and psychological treatment
Description: Medical treatment is naturalistic and evidence based according to international recommendations.~Psychological treatment is either group psychoeducation or group cognitive behavioural therapy.
Study NCT00253071 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prophylactic combined medical and psychological treatment
Description: Medical treatment is naturalistic and evidence based according to international recommendations.~Psychological treatment is either group psychoeducation or group cognitive behavioural therapy.
Study NCT01054209 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Warming with warming mattress
Description: Reusable pressure relieving warming mattress. Principle use is to warm patients to prevent hypothermia peri-operatively.~Inditherm Alpha systems, OTM1: 1900mm x 585mm
Study NCT01913613 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IASD
Description: IASD device implantation
Study NCT03175809 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PFM training
Description: The PFM training will be delivered with an electromyographic biofeedback (bEMG). In order to perform the muscular training, the Biotrainer software was used, the training protocol will follow a rationale of evolutionary complexity throughout each session. The training protocols will focus on both muscle relaxation and contraction training and coordination.The parameters for the biofeedback will be tailored to the participant's presentation and will be determined and adjusted between each session as needed by the treating therapist. The treatment parameters will be determined by the treating therapist based on the participant's assessment that will be conducted at each treatment session. The Maximum voluntary contraction will be assessed at the beginning of each training day.
Study NCT03175809 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PFM training
Description: The PFM training will be delivered with an electromyographic biofeedback (bEMG). In order to perform the muscular training, the Biotrainer software was used, the training protocol will follow a rationale of evolutionary complexity throughout each session. The training protocols will focus on both muscle relaxation and contraction training and coordination.The parameters for the biofeedback will be tailored to the participant's presentation and will be determined and adjusted between each session as needed by the treating therapist. The treatment parameters will be determined by the treating therapist based on the participant's assessment that will be conducted at each treatment session. The Maximum voluntary contraction will be assessed at the beginning of each training day.
Study NCT03175809 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: The dry needling technique will be applied to the abdominal muscles (external oblique, rectus abdominis), lumbar spine (lumbar multifidus and erector spinae) and hip muscles (piriformis, gluteus medius, psoas major and adductors). Both active of latent myofascial trigger points will be treated with sterile stainless steel needles (0.25x0.4 mm or 0.2x0,7mm, DongBang, Korea). After diagnosis of the area of muscle pain, the tight band of the muscle will be palpated and the needle will be introduced subcutaneously. The second insertion will be toward the muscle point until a local twitch response (LTR) is elicited. Then the needle will be removed and the area will be compressed for 30 seconds.
Study NCT00886626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: Exenatide, subcutaneous injection, 10 mcg, twice per day
Study NCT02701660 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electronic medication dispenser (medido)
Description: Automated dispense of medication through an electronic dispenser
Study NCT04136717 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Washout period
Description: During this period the patients will breath spontaneously oxygen titrated using the FreeO2 device with a SpO2 target set at 90%. The period duration is 30 minutes.
Study NCT04136717 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: NIV - FreeO2
Description: During this period the patients will receive NIV using FreeO2 device for oxygen titration with a SpO2 target set at 90%. Initially, the inspiratory pressure will be set to obtain a tidal volume between 6 to 8 mL/Kg of predictive body weight and positive end-expiratory end pressure (PEEP) at 5 centimeters of water (cmH2O).~After NIV initiation, the parameters can be adjusted to improve patient comfort. The period duration is 30 minutes.
Study NCT04136717 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Nasal High flow Oxygen therapy - FreeO2
Description: During this period the patients will receive NHFOT using the FreeO2 device for oxygen titration with a SpO2 target set at 90%. The high flow device will be set at 30 lpm.The period duration is 30 minutes.
Study NCT04136717 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: CPAP - Oxygen constant flow
Description: During this period, the patients will have their own CPAP with oxygen adjusted by hospital staff according to hospital protocol. The period duration is 15 minutes.
Study NCT04136717 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: CPAP - FreeO2
Description: During this period, the patients will have their own CPAP with oxygen adjusted using the FreeO2 device. SpO2 target will be set at 90% The period duration is 60 minutes.
Study NCT02843321 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T-cell infusion, influenza vaccination
Description: Donor derived infection-specific T-cells (with activity against CMV,adenovirus, EBV, VZV, Influenza, BKV and Aspergillus) and vaccination (with Fluvax)
Study NCT01290549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab Vedotin
Description: Participants will receive escalating intravenous dose of polatuzumab vedotin.
Study NCT01290549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab will be administered by an IV infusion at 375 mg/m\^2 body surface area dose q3w.
Study NCT03408639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CinnaPoietin®
Description: The starting dose of Erythropoietin is 60 (50-100) IU/kg body weight/week for naïve patients. Administration dose for patients who are treated with erythropoietin is similar dose of previously administered amount (IV or SC without any change). After then, dose adjustment will be done based on patients' response.
Study NCT03408639 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eprex®
Description: The starting dose of Erythropoietin is 60 (50-100) IU/kg body weight/week for naïve patients. Administration dose for patients who are treated with erythropoietin is similar dose of previously administered amount (IV or SC without any change). After then, dose adjustment will be done based on patients' response.
Study NCT03408639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nephrovit
Description: Nephrovit tablet is daily administered to all the patients.
Study NCT03408639 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nephrovit
Description: Nephrovit tablet is daily administered to all the patients.
Study NCT03408639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin B12 Injection
Description: Vitamin B12 is monthly injected to all the patients.
Study NCT03408639 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin B12 Injection
Description: Vitamin B12 is monthly injected to all the patients.
Study NCT00548639 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Statin Choice Decision Aid
Description: Paper based instrument with pictures indicating level of risk.
Study NCT00548639 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control Pamphlet
Description: ADA Diabetes Sheet
Study NCT02269098 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diabetes medication management
Description: As above plus- Follow-up intervention visits were at 24-72 hrs, 2 and 4 weeks. During each, further DSME was provided, BG logs reviewed, and diabetes medications adjusted as needed by the CDE. Meter and insulin injections skills were reinforced as needed. Outpatient navigation included securing a primary care appointment no later than 4 weeks after study completion. Final contact was via telephone at 90 days. The MMS© (Morisky Medication Adherence Survey) was taken at 2 and 4 weeks and during the final telephone visit. Interim return visits to the ED or admissions to the hospital were queried at each visit. A follow up HbA1C was obtained at week 4 using the POC A1CNow+ ®, and a venous HbA1C was drawn if the POC result was above 13% .
Study NCT02963779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2775240
Description: Administered orally
Study NCT02963779 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study NCT02963779 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apremilast
Description: Administered orally
Study NCT01689051 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: human glucagon-like peptide 1 (7-36)amide
Study NCT01689051 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: human glucagon-like peptide 1 (9-36)amide
Study NCT01287806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ulinastatin
Description: Resolved 4 vials of drugs in 100ml physiological saline solution,intravenously infused for 1-2h,tid,for continuous 10days
Study NCT01287806 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: blank group
Description: standard treatment
Study NCT00247715 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: algeldrate/magnesium oxide
Study NCT00247715 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ranitidine
Study NCT00247715 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: pantoprazole
Study NCT02243150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT03426774 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Gentle Jogger
Description: Passive Simulated Jogging device (Gentle Jogger)
Study NCT03426774 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gentle Jogger
Description: Passive Simulated Jogging device (Gentle Jogger)
Study NCT03426774 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Gentle Jumper
Description: Passive Simulated Jumping Device ( Gentle Jumper)
Study NCT03426774 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gentle Jumper
Description: Passive Simulated Jumping Device ( Gentle Jumper)
Study NCT02246205 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pancreaticoduodenectomy
Description: Pancreaticoduodenectomy is the classical operative technique to resect cephalic pancreatic cancer. In a first phase of the surgery, the resection may be performed. In the second phase, the digestive tract must be restored. We planify two different reconstruction techniques.
Study NCT02246205 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pancreaticoduodenectomy
Description: Pancreaticoduodenectomy is the classical operative technique to resect cephalic pancreatic cancer. In a first phase of the surgery, the resection may be performed. In the second phase, the digestive tract must be restored. We planify two different reconstruction techniques.
Study NCT01258751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05212377
Description: Single dose of up to 70 mg PF-05212377, delivered as .25 mg, 5 mg and/or 15 mg on study day 1
Study NCT01995656 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Capsule
Description: Administered orally
Study NCT01995656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3108743 - Capsule
Description: Administered orally
Study NCT01995656 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Solution
Description: Administered orally
Study NCT01995656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3108743 - Solution
Description: Administered orally
Study NCT02267343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-4538
Study NCT02267343 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo